Dartmouth prof’s biomed firm follows a more entrepreneurial path for its anti-cancer discovery




Officially launched in 2011, ImmuNext has already landed what could potentially be a $150 million deal with Johnson & Johnson that takes the company’s cancer-fighting technology from lab to fruition
CLICK TO VIEW THE SOURCE MATERIAL


Post a comment


You must sign in before you can post comments. If you are experiencing issues with your account please e-mail abuse@unionleader.com.